Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138803 | 0.91 | ADORA2A (0.60) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL5501190 | 0.91 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL7752324 | 0.90 | ADORA2A (0.59) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL195449 | 0.88 | ADORA3 (0.57) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL6829360 | 0.88 | ADORA2A (0.57) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL15413277 | 0.87 | ADORA2A (0.55) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL14782965 | 0.85 | ADORA2A (0.63) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL343478 | 0.83 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL14931005 | 0.83 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL62505 | 0.83 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2019-05-16 | — | — | US | disclosed |
| EP-1090137-A1 | PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS | Larova Biochemie GmbH (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067413-A1 | PRODUCTION OF POLYMERS FROM NUCLEOTIDIC AND/OR NON-NUCLEOTIDIC ELEMENTS USING ENZYMATIC METHODS | LAROVA BIOCHEMIE GMBH (DE) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | ADORA2A 3215/4885ADORA2B 2397/4885ADORA3 3185/4885 |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | ADORA2A 3215/4885ADORA2B 2397/4885ADORA3 3185/4885 |
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | ADORA2A 3215/4885ADORA2B 2397/4885ADORA3 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.